Probiotic prevention and treatment of colon cancer

Abstract

Methods are provided herein for preventing, delaying the onset of or reducing the progression of colorectal tumorigenesis in a subject identified as at risk of colorectal tumorigenesis, comprising adjusting the composition of gut microbiota in the subject via administering to the subject a composition comprising Bacteroides bacteria or administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising zwitterionic polysaccharide (ZPS). In another aspect, methods are provided for treating or ameliorating a colorectal cancer in a subject, comprising adjusting the composition of gut microbiota in the subject having the colorectal cancer. In a further aspect, methods are provided for relieving gastrointestinal (GI) distress of a subject having a colorectal condition, comprising: determining the colorectal condition of the subject; and relieving GI distress in the subject by adjusting the composition of gut microbiota in the subject.

What is claimed is: 
     
         1 . A method for preventing, delaying the onset of or reducing the progression of colorectal tumorigenesis in a subject identified as at risk of colorectal tumorigenesis, comprising:
 adjusting the composition of gut microbiota in the subject via administering to the subject a composition comprising  Bacteroides  bacteria.   
     
     
         2 . The method of  claim 1 , wherein the  Bacteroides  bacteria is  B. fragilis, B. thetaiotaomicron, B. vulgatus , or a mixture thereof. 
     
     
         3 . The method of  claim 1 , wherein the composition is a probiotic composition, a neutraceutical composition, a pharmaceutical composition, or a mixture thereof. 
     
     
         4 . The method of  claim 1 , wherein the composition is administered via fecal transplantation or oral administration. 
     
     
         5 . The method of  claim 1 , wherein the composition is administered intermittently, periodically, continuously, or chronically. 
     
     
         6 . The method of  claim 1 , comprising diagnosing the subject with an intestinal inflammatory condition. 
     
     
         7 . The method of  claim 6 , wherein the intestinal inflammatory condition is selected from the group consisting of inflammatory bowel disease (IBD), Crohn's disease (CD), and ulcerative colitis (UC). 
     
     
         8 . The method of  claim 1 , comprising assessing the risk of colorectal tumorigenesis of the subject. 
     
     
         9 . The method of  claim 8 , wherein assessing the risk of colorectal tumorigenesis of the subject comprises looking for a family history of colorectal cancer of the subject, identifying a genetic mutation associated with colorectal cancer in the subject, testing for dysbiosis in the subject, or a combination thereof. 
     
     
         10 . The method of  claim 9 , wherein the dysbiosis comprises an over-representation of  Proteus mirabilis  and/or  Klebsiella Pneumonia.    
     
     
         11 . The method of  claim 1 , wherein the tumor-free time of the subject in which the composition of gut microbiota has been adjusted is increased in comparison to a reference tumor-free time in one or more subjects in which the composition of gut microbiota has not been adjusted. 
     
     
         12 . The method of  claim 1 , wherein the total size of one or more tumors in the subject in which the composition of gut microbiota has been adjusted is decreased in comparison to a reference total tumor size in one or more subjects in which the composition of gut microbiota has not been adjusted. 
     
     
         13 . The method of  claim 1 , wherein the total number of the tumors in the subject in which the composition of gut microbiota has been adjusted is decreased in comparison to a reference total tumor number in one or more subjects in which the composition of gut microbiota has not been adjusted. 
     
     
         14 . A method for preventing, delaying the onset of or reducing the progression of colorectal tumorigenesis in a subject at risk of colorectal tumorigenesis, comprising:
 administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising zwitterionic polysaccharide (ZPS).   
     
     
         15 . The method of  claim 14 , wherein the ZPS is derived from bacteria. 
     
     
         16 . The method of  claim 14 , wherein the ZPS is polysaccharide A (PSA). 
     
     
         17 . The method of  claim 14 , comprising diagnosing the subject with an intestinal inflammatory condition. 
     
     
         18 . The method of  claim 17 , wherein the intestinal inflammatory condition is selected from the group consisting of inflammatory bowel disease (IBD), Crohn's disease (CD), and ulcerative colitis (UC). 
     
     
         19 . The method of  claim 14 , comprising assessing the risk of colorectal tumorigenesis of the subject. 
     
     
         20 . The method of  claim 19 , wherein assessing the risk of colorectal tumorigenesis of the subject comprises looking for a family history of colorectal cancer of the subject, identifying a genetic mutation associated with colorectal cancer in the subject, testing for dysbiosis in the subject, or a combination thereof. 
     
     
         21 . The method of  claim 14 , wherein the tumor-free time of the subject to which the pharmaceutical composition has been administered is increased in comparison to a reference tumor-free time in one or more subjects to which the pharmaceutical composition has not been administered. 
     
     
         22 . The method of  claim 14 , wherein the total size of one or more tumors in the subject to which the pharmaceutical composition has been administered is decreased in comparison to a reference total tumor size in one or more subjects to which the pharmaceutical composition has not been administered. 
     
     
         23 . The method of  claim 14 , wherein the total number of one or more tumors in the subject to which the pharmaceutical composition has been administered is decreased in comparison to a reference total tumor number in one or more subjects to which the pharmaceutical composition has not been administered. 
     
     
         24 . A method for treating or ameliorating a colorectal cancer in a subject, comprising:
 adjusting the composition of gut microbiota in the subject having the colorectal cancer.   
     
     
         25 . The method of  claim 24 , wherein adjusting the composition of gut microbiota of the subject comprises administering to the subject a composition comprising  Bacteroides  bacteria, wherein the  Bacteroides  bacteria is  B. fragilis, B. thetaiotaomicron, B. vulgatus , or a mixture thereof. 
     
     
         26 . The method of  claim 25 , wherein the composition is administered via fecal transplantation or oral administration. 
     
     
         27 . A method for relieving gastrointestinal (GI) distress of a subject having a colorectal condition, comprising:
 determining the colorectal condition of the subject; and   relieving GI distress in the subject by adjusting the composition of gut microbiota in the subject.   
     
     
         28 . The method of  claim 27 , wherein the colorectal condition is a colorectal cancer. 
     
     
         29 . The method of  claim 27 , wherein the colorectal condition is an intestinal inflammatory condition.